Protocol Summary Clause Samples

POPULAR SAMPLE Copied 2 times
Protocol Summary. Study Sponsor Verily Life Sciences LLC Study Description This study seeks to understand patient diagnostic and treatment journey and positive airway pressure (PAP) therapy compliance for Verily Sleep Apnea (VSA) program/app users. Participants will enroll remotely and may undergo a home sleep test (HST). Upon confirmation of obstructive sleep apnea (OSA) and prescription of PAP therapy, the participant will begin using the VSA app to supplement PAP treatment. After 90 days of active participation, the participant will be given instructions for follow-up care, as indicated. This study will take a decentralized approach. Recruitment, enrollment, consultation, testing, coaching and active participation with the VSA app will take place remotely.
View Source
Protocol Summary. Principal Investigator Information: (Name, Institution, Address, Telephone/Fax Number, E-mail Address)
View Source
Protocol Summary. ‌ This protocol describes an immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites. This protocol meets the objectives of component D in the Flu VE Network Cooperative Agreement (IP16-004), including enrollment of eligible persons into a cohort, administration of a licensed or authorized under emergency use authorization (EUA) mRNA COVID-19 vaccine (Moderna COVID-19 Vaccine) and licensed quadrivalent cell culture-based influenza vaccine (Flucelvax; ccIIV4), collection and testing of blood specimens, administration of enrollment surveys, protection of personally identifiable information, transfer of a HIPAA-limited dataset to the Network Coordinating Center (NCC) and CDC, and creation of a coded individual-level dataset according to a data management agreement.
View Source
Protocol Summary. The Protocol Summary for the Combined Therapy Study is attached hereto.
View Source
Protocol Summary. This study is a prospective, single-center and non-comparative study. The study will include subjects must be ≥ 20 years of age with cataract who would be eligible to receive a TFNT20 lens in at least one eye based on a new Alcon Toric calculator that incorporates ocular trends in Toric IOL planning. Subject with no ocular pathology that could confound study outcome, must require clear cornea cataract extraction, and must desire an IOL that provides the potential for near, intermediate and distance vision and corrects astigmatism. Potential subjects will be screened for enrollment into this clinical trial. Those qualifying will attend a total 5 visits. If the investigational products will be implanted to both eye, the maximum number of visits is total 9 visits. Primary endpoint data will be collected at the final visit, Visit3/3A (30-60 days post implantation). No interim analysis is planned. Investigational product type Device Study type Interventional Investigational products Test Product: AcrySof IQ PanOptix Toric Intraocular Lens Model TFNT20 (hereinafter called "TFNT20") Control Product: Not applicable Purpose and rationale The purpose of this study is to evaluate effectiveness and safety of the TFNT20 when implanted to replace the natural lens following cataract removal. this is intended to confirm the safety of the test product and examine its effectiveness as a Toric lens by examining the subject’s astigmatism power.
View Source

Related to Protocol Summary

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Budget Summary Other Sources (Page BudgetSum 2-3 - Acct 7000), must equal Other Uses (BudgetSum 2-3 - Acct. 8000). Estimated Beginning Fund Balance July,1 2020 for all Funds (Cells C3 - K3) (Line must have a number or zero. Do not leave blank.) OK Estimated Activity Fund Beginning Fund Balance July,1 2020 (Cell C83) (Cell must have a number or zero. Do not leave blank.) OK Transfer Among Funds (Funds 10, 20, 40 - Acct 7130 - Cells C29, D29, F29), must equal (Funds 10, 20 & 40 - Acct 8130 - Cells C52, D52, F52). OK Transfer of Interest (Funds 10 thru 90 - Acct 7140 - Cells C30:K30), must equal (Funds 10 thru 60, & 80 - Acct 8140 - Cells C53:H53, J53). OK Transfer to Debt Service to Pay Principal on Capital Leases (Fund 30 - Acct 7400 - Cell E39) must equal (Funds 10, 20 & 60 - Acct 8400 Cells C57:H60). OK Transfer to Debt Service to Pay Interest on Capital Leases (Fund 30 - Acct 7500 - Cell E40) must equal (Funds 10, 20 & 60 - Acct 8500 - Cells C61:H64). OK Transfer to Debt Service Fund to Pay Principal on Revenue Bonds (Fund 30 - Acct 7600 - Cell E41) must equal (Funds 10 & 20 - Acct 8600 - Cells C65:D68). OK Transfer to Debt Service to Pay Interest on Revenue Bonds (Fund 30 - Acct 7700 - Cell E42) must equal (Funds 10 & 20 - Acct 8700 - Cells C69:D72). OK Transfer to Capital Projects Fund (Fund 60 - Acct 7800 - Cell H43) must equal (Fund 10 & 20, Acct 8800 - Cells C73:D76). OK

  • JOB SUMMARY Vouches sample transaction in audit verification assignments and submits findings to supervisor; • Records proceedings of entry and exit conferences; • Collects and analyses data and statistics; • Prepares audit working papers for review by supervisor; • Undertakes any other duties that may be assigned by the Chief Internal Audit Technician.

  • Risk Analysis The Custodian will provide the Fund with a Risk Analysis with respect to Securities Depositories operating in the countries listed in Appendix B. If the Custodian is unable to provide a Risk Analysis with respect to a particular Securities Depository, it will notify the Fund. If a new Securities Depository commences operation in one of the Appendix B countries, the Custodian will provide the Fund with a Risk Analysis in a reasonably practicable time after such Securities Depository becomes operational. If a new country is added to Appendix B, the Custodian will provide the Fund with a Risk Analysis with respect to each Securities Depository in that country within a reasonably practicable time after the addition of the country to Appendix B.